

List of Tables

| | Page Number |
|------------|---|
| Table 1* | xix |
| Table 1-1 | Summary of U.S. and European Legislation and Statutory Protocol |
| | Requirements for Pyrogenicity Testing 1-5 |
| Table 2-1 | <i>In Vitro</i> Pyrogen Test Method Components 2-3 |
| Table 2-2 | Prediction Model Used for <i>In Vitro</i> Pyrogen Test Methods 2-8 |
| Table 3-1 | Parenteral Drugs Used in the Validation Studies for Determining Test Method Accuracy 3-2 |
| Table 3-2 | Parenteral Drugs Used in the Validation Studies for Determining Test Method Reproducibility 3-2 |
| Table 4-1 | Test Guidelines for the Rabbit Pyrogen Test 4-3 |
| Table 4-2 | Decision Criteria for Determining a Pyrogenic Response in the Rabbit Pyrogen Test 4-6 |
| Table 6-1* | Accuracy of <i>In Vitro</i> Pyrogen Test Methods 6-2 |
| Table 6-2 | Predictivity of <i>In Vitro</i> Pyrogen Test Method for Each Endotoxin Spike Concentration 6-5 |
| Table 7-1 | Intralaboratory Repeatability Assessed with Saline Spiked with WHO-LPS 94/580 7-3 |
| Table 7-2 | Intralaboratory Reproducibility of <i>In Vitro</i> Pyrogen Test Methods 7-5 |
| Table 7-3 | Interlaboratory Reproducibility of <i>In Vitro</i> Pyrogen Test Methods 7-7 |
| Table 7-4 | Interlaboratory Reproducibility of <i>In Vitro</i> Pyrogen Test Methods 7-8 |
| Table 9-1 | Results of Pyrogen Testing of Pharmaceutical/Biological Products in the Human PBMC Assay, the BET, and the RPT 9-2 |
| Table 9-2 | Results of Pyrogen Testing of Pharmaceutical/Biological Products by the Human WB Culture Assay, the BET, and the RPT 9-3 |
| Table 9-3 | IL-6 Production from WB after Exposure to Endotoxin or Five Infanrix® Vaccines 9-5 |
| Table 9-4 | IL-6 Production by MM6 Cells after Exposure to Endotoxin or Five Infanrix® Vaccines 9-6 |
| Table 9-5 | Pyrogenic Activity of Blood Preparations for Parenteral Use 9-9 |
| Table 9-6 | Pyrogenic Activity of Vaccine Preparations 9-10 |
| Table 9-7 | Comparison of the WB Test, BET, and the RPT for Detecting Pyrogens in Production Batches of Biological Products 9-12 |
| Table 9-8 | Results of Pyrogen Testing of Batches of Therapeutic HSA Using the MM6/IL-6, BET, and RPT 9-13 |
| Table 9-9 | Comparison of the Application Spectra of the RPT, the BET, and the Human WB Assay (PyroCheck®) 9-14 |
| Table 11-1 | Cost Estimates for the RPT and <i>In Vitro</i> Pyrogen Tests 11-3 |

*Tables 1 and 6-1 are identical. Table 1 provides supporting information for the Executive Summary, while Table 6-1 provides the information in Section 6.1, where test method accuracy is discussed in greater detail.